Chief Financial Officer
Michael Wyzga is the CFO at Aura. Prior to joining Aura, he served as President, CEO and member of the board of directors of Radius Health, Inc., a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis. Before that, he served as CFO and Executive Vice President of Genzyme Corporation for 12 years. Prior to joining Genzyme, Michael served in various senior-level positions in the high-tech industry, including at Lotus Development and Digital Equipment Company. He received a BS from Suffolk University and an MBA from Providence College.
Michael currently serves on the board of directors of Akebia Therapeutics, Inc., a public pharmaceutical company; Oncomed Pharmaceuticals, Inc., a public oncology company; Exact Sciences, a public modular diagnostics company; and GenSight, a clinical-stage biotechnology company. He also served on the board of directors of Idenix Pharmaceuticals until its acquisition by Merck in 2014 and Prosensa Therapeutics until its acquisition by BioMarin Pharmaceuticals in 2014.